Blog
Published July 6, 2021
Executive Summary
The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance
Since 2017, on average, a significant price discount of 44-61% was required for products to achieve a positive listing on the NRDL
Based on average 2018 sales data, products included on the 2017 NRDL were able to achieve an increase in sales revenue (188%) despite the steep average…
Read Now
Blog
Published June 2, 2021
Executive Summary
The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland
The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years
The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date
Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…
Read Now
Blog
Published May 25, 2021
Executive Summary
Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing success
Dynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access outcomes
Trinity’s Take: In this article, Trinity uses select combination case studies to highlight the key elements to consider when thinking through price / access strategy for a novel combination
Evaluation of the Novel Combinations Landscape
The pursuit of a successful…
Read Now
Blog
Published February 19, 2021
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam…
Read Now
Blog
Published November 3, 2020
Executive Summary
Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially
To date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approval
There have been multiple challenges involved when trying to successfully commercialize the products, but the landscape looks…
Read Now
Blog
Published November 3, 2020
Written by Tom Rutkowski and Patrick Buck…
Read Now
Blog
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Read Now
Blog
Published September 22, 2020
Executive Summary
Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment
Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare
New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Read Now
Blog
Published August 25, 2020
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…
Read Now
Blog
Published July 14, 2020
Executive Summary
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake
Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization
Pharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely to…
Read Now
